Shareholder Class Action Filed Against Phreesia After Guidance Cut

Firms say the March guidance revision exposed misleading statements about growth drivers and are urging investors to seek lead-plaintiff status by mid-July.

Overview

Phreesia reduced its fiscal 2027 revenue growth outlook on March 30, 2026, and the stock fell about 26.6% the next trading day when investors reacted to weaker pharmaceutical marketing commitments.
Plaintiff lawyers allege the company made false or misleading statements about its long-term growth outlook and the reliability of pharmaceutical marketing commitments as a revenue driver.
Multiple plaintiff firms have filed or publicized the suit and are contacting shareholders who bought PHR between May 8, 2025 and March 30, 2026 to join the case.
Shareholders who want to seek appointment as lead plaintiff must move the court by July 13, 2026; the putative class has not been certified and the case remains in the early procedural phase.
Legal success is uncertain because plaintiffs must prove material misstatements, reliance, loss causation and scienter, and the litigation could prompt closer scrutiny of how companies rely on marketing commitments in public guidance.